MARIA TERESA DONATO MARTIN-rekin lankidetzan egindako argitalpenak (21)

2016

  1. Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis

    Toxicology and Applied Pharmacology, Vol. 302, pp. 1-9

  2. Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to develop new predictive biomarkers for early drug development

    Toxicology Letters, Vol. 263, pp. 58-67

  3. Human upcyte hepatocytes: Characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing

    Toxicological Sciences, Vol. 152, Núm. 1, pp. 214-229

2015

  1. Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease

    Molecular Pharmacology, Vol. 87, Núm. 4, pp. 582-594

2014

  1. A simple transcriptomic signature able to predict drug-induced hepatic steatosis

    Archives of Toxicology, Vol. 88, Núm. 4, pp. 967-982

2013

  1. Hepatic cell lines for drug hepatotoxicity testing: Limitations and strategies to upgrade their metabolic competence by gene engineering

    Current Drug Metabolism, Vol. 14, Núm. 9, pp. 946-968

2009

  1. Cytochrome P450 and steatosis

    Current Drug Metabolism, Vol. 10, Núm. 7, pp. 692-699

2008

  1. Desarrollo, análisis y optimización de modelos celulares hepáticos para estudios de fármaco-toxicología y terapia celular

    Anales de la Real Academia Nacional de Farmacia, Núm. 2, pp. 283-308

  2. Desarrollo, análisis y optimización de modelos celulares hepáticos para estudios de fármaco-toxicología y terapia celular

    Anales de la Real Academia Nacional de Farmacia, Vol. 74, Núm. 2, pp. 283-306

2007

  1. Transcriptional regulation and expression of CYP3A4 in hepatocytes

    Current Drug Metabolism, Vol. 8, Núm. 2, pp. 185-194

2004

  1. Human hepatocytes in primary culture: The choice to investigate drug metabolism in man

    Current Drug Metabolism, Vol. 5, Núm. 5, pp. 443-462

2003

  1. Diclofenac induces apoptosis in hepatocytes

    Toxicology in Vitro

  2. Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS

    Biochemical Pharmacology, Vol. 66, Núm. 11, pp. 2155-2167

  3. Human hepatocytes as a tool for studying toxicity and drug metabolism

    Current Drug Metabolism, Vol. 4, Núm. 4, pp. 292-312

2001

  1. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2

    European Journal of Biochemistry, Vol. 268, Núm. 5, pp. 1448-1459

2000

  1. Expression of liver specific-genes in hepatocytes cultured in collagen gel matrix.

    Progress in molecular and subcellular biology, Vol. 25, pp. 89-104

1998

  1. Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture

    Journal of Pharmacology and Experimental Therapeutics, Vol. 284, Núm. 2, pp. 760-767

  2. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix

    Journal of Cellular Physiology, Vol. 177, Núm. 4, pp. 553-562

  3. Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes

    Journal of Pharmacology and Experimental Therapeutics, Vol. 285, Núm. 1, pp. 127-134

1997

  1. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-γ in human hepatocytes

    Journal of Pharmacology and Experimental Therapeutics, Vol. 281, Núm. 1, pp. 484-490